New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities
More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies
New Data Presented at ESTRO
The CyberKnife platform's unique robotic technology, non-coplanar beam delivery and Synchrony® technology enable the treatment of more anatomical sites with ultra-hypofractionated radiotherapy, helping to make a clinical difference for patients every day.
- Neurologic Disorders: sub-millimeter accuracy enables delivery of stereotactic radiosurgery (SRS) to a diverse patient population. Studies indicate CyberKnife SRS can:
- Increase survival for patients with recurrent high-grade gliomas.
- Offer patients with acoustic neuromas a well-tolerated, effective regimen with excellent tumor control and acceptable hearing preservation.
- Provide good local control with low toxicity when treating HER2-breast cancer brain metastasis.
- Breast Cancer: multiple studies show the CyberKnife System with Synchrony can provide promising results in early-stage patients. Studies evaluating the system found:
- Single-dose pre-operative radiation therapy is a feasible, well-tolerated technique with a promising rate of response.
- Four-fraction post-lumpectomy stereotactic accelerated partial breast irradiation (S-APBI) is a feasible and reproducible technique. Treatment was well-tolerated and cosmetic outcomes were rated good or excellent by all patients.
- Five-fraction S-APBI post-lumpectomy is well-tolerated.
- Innovative Techniques: precise and efficient radiation dose delivery helps make it possible for a wide range of patients to receive treatment, including those with complex indications. Studies undertaken with TomoHelical™ Treatment Delivery demonstrate:
- Total marrow irradiation in combination with tandem autologous transplant can provide favorable long-term (10 years) outcomes and toxicity in multiple myeloma patients.
- A simultaneous integrated boost and intensity-modulated radiation therapy (IMRT) can offer favorable outcomes and acceptable toxicity in the treatment of anal cancer.
- The combination of IMRT and high-dose-rate intra-cavity brachytherapy can provide excellent local control and favorable overall survival for patients with non-metastatic cervical cancer.
- Single-fraction lumbopelvic bone irradiation is a promising, very effective treatment option with excellent tolerance rates for patients with multiple painful bone metastases.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to planned investments in technology, new products and innovations, clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the company and those of its customers and suppliers, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director, Accuray
+1 (408) 789-4426
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-data-presented-at-estro-2022-reinforce-benefits-of-accuray-cyberknife-and-tomotherapy-platforms-across-a-range-of-indications-and-complexities-301543379.html